Difference between revisions of "Etoposide (Vepesid)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "[https://online.lexi.com/lco/action/login UpToDate Lexidrug]")
(72 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.<ref name="insert">[http://packageinserts.bms.com/pi/pi_etopophos.pdf Etoposide (Vepesid) package insert]</ref><ref>[[Media:Etoposide.pdf | Etoposide (Vepesid) package insert (locally hosted backup)]]</ref>
+
Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.<ref name="insert">[http://packageinserts.bms.com/pi/pi_etopophos.pdf Etoposide (Vepesid) package insert]</ref><ref>[[:File:Etoposide.pdf | Etoposide (Vepesid) package insert (locally hosted backup)]]</ref>
 
<br>Route: IV, PO
 
<br>Route: IV, PO
 
<br>Extravasation: [[irritant]]
 
<br>Extravasation: [[irritant]]
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
 +
 
 +
==Diseases for which it is established ''(work in progress)''==
 +
*Non-Hodgkin lymphoma
 +
**[[Follicular lymphoma]]
 +
**[[Peripheral T-cell lymphoma]]
  
 
==Diseases for which it is used==
 
==Diseases for which it is used==
−
*[[Acute lymphocytic leukemia]]
+
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3">
 +
*[[Acute lymphoblastic leukemia, infant]]
 
*[[Acute myeloid leukemia]]
 
*[[Acute myeloid leukemia]]
 
*[[Acute promyelocytic leukemia]]
 
*[[Acute promyelocytic leukemia]]
−
*[[Aggressive Non-Hodgkin lymphoma]]
+
*[[Carcinoma of unknown primary]]
−
*[[Bone cancer]]
+
*[[Adrenocortical carcinoma]]
−
*[[Unknown primary | Cancer of Unknown Primary]]
+
*[[Adult T-cell leukemia-lymphoma]]
−
*[[Central nervous system (CNS) cancer]]
+
*[[Anaplastic glioma]]
 +
*[[Anaplastic large cell lymphoma]]
 +
*[[B-cell acute lymphoblastic leukemia]]
 +
*[[T-cell acute lymphoblastic leukemia]]
 +
*[[Burkitt lymphoma]]
 +
*[[Cholangiocarcinoma]]
 +
*[[CNS lymphoma]]
 +
*[[Diffuse large B-cell lymphoma]]
 
*[[Esophageal cancer]]
 
*[[Esophageal cancer]]
−
*[[Follicular lymphoma]]
+
**[[Esophageal adenocarcinoma]]
−
*[[Hepatobiliary cancer]]
+
**[[Esophageal squamous cell carcinoma]]
 +
*[[Ewing sarcoma]]
 +
*[[Extranodal NK- and T-cell lymphoma, nasal type]]
 +
*[[Gallbladder cancer]]
 +
*[[Gestational trophoblastic neoplasia]]
 +
*[[Hemophagocytic lymphohistiocytosis]]
 
*[[HIV-associated lymphoma]]
 
*[[HIV-associated lymphoma]]
−
*[[Hodgkin lymphoma]]
+
*[[Classical Hodgkin lymphoma]]
 
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]]
 
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]]
 +
*[[Kaposi sarcoma]]
 +
*[[Langerhans cell histiocytosis]]
 +
*[[Low-grade glioma]]
 +
**[[Low-grade glioma, pediatric]]
 
*[[Mantle cell lymphoma]]
 
*[[Mantle cell lymphoma]]
 +
*[[Mediastinal gray-zone lymphoma]]
 +
*[[Medulloblastoma]]
 
*[[Multiple myeloma]]
 
*[[Multiple myeloma]]
−
*[[Neuroendocrine tumors]]
+
*[[Neuroblastoma]]
 +
*[[NK- and T-cell lymphoma]]
 
*[[Non-small cell lung cancer]]
 
*[[Non-small cell lung cancer]]
 +
**[[Non-small cell lung cancer, nonsquamous]]
 +
*[[Osteosarcoma]]
 
*[[Ovarian cancer]]
 
*[[Ovarian cancer]]
−
*[[Sarcoma]]
+
*[[Primary mediastinal B-cell lymphoma]]
 +
*[[Rhabdomyosarcoma]]
 +
*[[Soft tissue sarcoma]]  
 
*[[Small cell lung cancer]]
 
*[[Small cell lung cancer]]
−
*[[T-cell lymphoma]]
 
 
*[[Testicular cancer]]
 
*[[Testicular cancer]]
 
*[[Thymoma]]
 
*[[Thymoma]]
−
*[[Transplant conditioning regimens]]
+
*[[Transformed lymphoma]]
 +
</div>
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://chemocare.com/chemotherapy/drug-info/etoposide.aspx Etoposide (Vepesid) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/etoposide.aspx Etoposide (Vepesid) patient drug information (Chemocare)]</ref>
+
*[http://packageinserts.bms.com/pi/pi_etopophos.pdf Etoposide (Vepesid) package insert]<ref name="insert"></ref>
 +
*[https://chemocare.com/druginfo/etoposide.aspx Etoposide (Vepesid) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/etoposide.aspx Etoposide (Vepesid) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]</ref>
 +
 +
==History of changes in FDA indication==
 +
*1983-11-10: Initial FDA approval for refractory [[Testicular cancer | testicular tumors]]. ''(No supporting studies are cited)''
 +
*Uncertain date: Approed for [[small cell lung cancer]], in combination with cisplatin, as first-line treatment. ''(Based on Hainsworth et al. 1995)''
 +
==History of changes in EMA indication==
 +
*1980-07-09: EURD
 +
==History of changes in PMDA indication==
 +
*2012-02-22: New additional indication and a new dosage for the treatment of [[ovarian cancer]] which has progressed after cancer chemotherapy.
 +
*2019-03-26: New indication for the treatment prior to tumor-specific T-cell infusion therapy.
  
 
==Also known as==
 
==Also known as==
−
Abic Etoposide, Aside, Beposid, Bioposide, BO RUI, Bristol VP-16, Celltop, Citodox, Epocin, Eposid, Eposide, Eposido, Eposin, Epsidox, ETO, Etocris, Etomedac, Etonolver, Etopofos, Etopophos, Etopos, Etoposid, Etoposide Abic, Etoposid Ebewe, Etoposide Bigmar, Etoposide BVI, Etoposide Dakota, Etoposide DBL, Etoposide DUP, Etoposide Ebewe, Etoposide Eurocept, Etoposide Merck, Etoposide Pfizer, etoposide phosphate, Etoposide Teva, Etoposid Mayne, Etoposido, Etoposido Delta Farma, Etoposido Ferrer, Etoposido GI Kendr, Etoposido Servycal, Etoposido Varifarm, Etoposid Proreo, Etoposid Teva, Etopoxan, Etopul, Etosid, Etosin, Eunades CS, Euvaxon, Exitop, Fytop, Fytosid, HAI WEI LIN, Labimion, Lastet, Lastet S, Neoplaxol, Nexvep, Onkoposid, Optasid, P&U Etoposide, Percas, Posid, Posidon, Posyd, Riboposid, Sintopozid, Toposar, Toposide, Toposin, Topresid, Tosuben, Vepefos, Vepeside, Vepesid K, Vepesid S, Vepesid VP-16, Vepsid, Vepside, VP-16, VP-TEC, VP 16213
+
*'''Code names:''' VP-16, VP-TEC, VP-16213
 +
*'''Generic name:''' etoposide phosphate
 +
*'''Brand names:'''
 +
{| class="wikitable" style="text-align:center;"
 +
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms'''
 +
|-
 +
|Aside
 +
|Beposid
 +
|Bioposide
 +
|Celltop
 +
|Citodox
 +
|Epocin
 +
|Eposid
 +
|Eposide
 +
|-
 +
|Eposido
 +
|Eposin
 +
|Epsidox
 +
|ETO
 +
|Etocris
 +
|Etomedac
 +
|Etonolver
 +
|Etopofos
 +
|-
 +
|Etopophos
 +
|Etopos
 +
|Etoposid
 +
|Etoposido
 +
|Etopoxan
 +
|Etopul
 +
|Etosid
 +
|Etosin
 +
|-
 +
|Eunades CS
 +
|Euvaxon
 +
|Exitop
 +
|Fytop
 +
|Fytosid
 +
|Labimion
 +
|Lastet
 +
|Lastet S
 +
|-
 +
|Neoplaxol
 +
|Nexvep
 +
|Onkoposid
 +
|Optasid
 +
|Percas
 +
|Posid
 +
|Posidon
 +
|Posyd
 +
|-
 +
|Riboposid
 +
|Sintopozid
 +
|Toposar
 +
|Toposide
 +
|Toposin
 +
|Topresid
 +
|Tosuben
 +
|Vepefos
 +
|-
 +
|Vepesid
 +
|Vepeside
 +
|Vepsid
 +
|Vepside
 +
|-
 +
|}
  
 
==References==
 
==References==
 
<references/>
 
<references/>
  
−
[[Category:Drug index]]
+
[[Category:Drugs]]
−
[[Category:Chemotherapy]]
+
[[Category:Intravenous medications]]
−
[[Category:Irritant chemotherapy]]
+
[[Category:Oral medications]]
−
[[Category:Topoisomerase inhibitors]]
+
 
 +
[[Category:Irritant]]
 +
[[Category:Topoisomerase II inhibitors]]
 +
 
 +
[[Category:Acute lymphoblastic leukemia, infant medications]]
 
[[Category:Acute myeloid leukemia medications]]
 
[[Category:Acute myeloid leukemia medications]]
−
[[Category:Bone cancer medications]]  
+
[[Category:Acute promyelocytic leukemia medications]]
−
[[Category:Cancer of unknown primary medications]]  
+
[[Category:Carcinoma of unknown primary medications]]
 +
[[Category:Adrenocortical carcinoma medications]]
 +
[[Category:Adult T-cell leukemia-lymphoma medications]]
 +
[[Category:Anaplastic glioma medications]]
 +
[[Category:Anaplastic large cell lymphoma medications]]
 +
[[Category:B-cell acute lymphoblastic leukemia medications]]
 +
[[Category:T-cell acute lymphoblastic leukemia medications]]
 +
[[Category:Burkitt lymphoma medications]]
 +
[[Category:Cholangiocarcinoma medications]]
 +
[[Category:CNS lymphoma medications]]
 +
[[Category:Diffuse large B-cell lymphoma medications]]
 +
[[Category:Esophageal adenocarcinoma medications]]
 
[[Category:Esophageal cancer medications]]
 
[[Category:Esophageal cancer medications]]
−
[[Category:Hepatobiliary cancer medications]]
+
[[Category:Esophageal squamous cell carcinoma medications]]
−
[[Category:Hodgkin lymphoma medications]]
+
[[Category:Ewing sarcoma medications]]
 +
[[Category:Extranodal NK- and T-cell lymphoma, nasal type medications]]
 +
[[Category:Follicular lymphoma medications]]
 +
[[Category:Gallbladder cancer medications]]
 +
[[Category:Gestational trophoblastic neoplasia medications]]
 +
[[Category:Hemophagocytic lymphohistiocytosis medications]]
 +
[[Category:HIV-associated lymphoma medications]]
 +
[[Category:Classical Hodgkin lymphoma medications]]
 +
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]]
 +
[[Category:Langerhans cell histiocytosis medications]]
 +
[[Category:Low-grade glioma medications]]
 +
[[Category:Low-grade glioma, pediatric medications]]
 +
[[Category:Mantle cell lymphoma medications]]
 +
[[Category:Mediastinal gray-zone lymphoma medications]]
 +
[[Category:Medulloblastoma medications]]
 
[[Category:Multiple myeloma medications]]
 
[[Category:Multiple myeloma medications]]
−
[[Category:Non-Hodgkin lymphoma medications]]
+
[[Category:Neuroblastoma medications]]
 +
[[Category:Neuroendocrine carcinoma medications]]
 +
[[Category:NK- and T-cell lymphoma medications]]
 
[[Category:Non-small cell lung cancer medications]]
 
[[Category:Non-small cell lung cancer medications]]
 +
[[Category:Non-small cell lung cancer, nonsquamous medications]]
 +
[[Category:Osteosarcoma medications]]
 
[[Category:Ovarian cancer medications]]
 
[[Category:Ovarian cancer medications]]
 +
[[Category:Peripheral T-cell lymphoma medications]]
 +
[[Category:Primary mediastinal B-cell lymphoma medications]]
 +
[[Category:Rhabdomyosarcoma medications]]
 +
[[Category:Soft tissue sarcoma medications]]
 
[[Category:Small cell lung cancer medications]]
 
[[Category:Small cell lung cancer medications]]
 
[[Category:Testicular cancer medications]]
 
[[Category:Testicular cancer medications]]
 
[[Category:Thymoma medications]]
 
[[Category:Thymoma medications]]
−
[[Category:Transplant medications]]
+
[[Category:Transformed lymphoma medications]]
 +
[[Category:Kaposi sarcoma medications]]
 +
 
 +
[[Category:FDA approved in 1983]]
 +
[[Category:EMA approved in 1980]]
 +
[[Category:WHO Essential Cancer Medicine]]

Revision as of 01:27, 27 June 2024

General information

Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV, PO
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1983-11-10: Initial FDA approval for refractory testicular tumors. (No supporting studies are cited)
  • Uncertain date: Approed for small cell lung cancer, in combination with cisplatin, as first-line treatment. (Based on Hainsworth et al. 1995)

History of changes in EMA indication

  • 1980-07-09: EURD

History of changes in PMDA indication

  • 2012-02-22: New additional indication and a new dosage for the treatment of ovarian cancer which has progressed after cancer chemotherapy.
  • 2019-03-26: New indication for the treatment prior to tumor-specific T-cell infusion therapy.

Also known as

  • Code names: VP-16, VP-TEC, VP-16213
  • Generic name: etoposide phosphate
  • Brand names:
Synonyms
Aside Beposid Bioposide Celltop Citodox Epocin Eposid Eposide
Eposido Eposin Epsidox ETO Etocris Etomedac Etonolver Etopofos
Etopophos Etopos Etoposid Etoposido Etopoxan Etopul Etosid Etosin
Eunades CS Euvaxon Exitop Fytop Fytosid Labimion Lastet Lastet S
Neoplaxol Nexvep Onkoposid Optasid Percas Posid Posidon Posyd
Riboposid Sintopozid Toposar Toposide Toposin Topresid Tosuben Vepefos
Vepesid Vepeside Vepsid Vepside

References

  1. ↑ 1.0 1.1 1.2 Etoposide (Vepesid) package insert
  2. ↑ Etoposide (Vepesid) package insert (locally hosted backup)
  3. ↑ Etoposide (Vepesid) patient drug information (Chemocare)
  4. ↑ Etoposide (Vepesid) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Etoposide_(Vepesid)&oldid=87022"